Prescription Drug News and Research

RSS

FDA Advisory Committee recommends marketing approval for Auxilium's XIAFLEX to treat Dupuytren's contracture

Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the Arthritis Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) recommended by a unanimous vote of 12 to 0 that XIAFLEX™ (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, be granted marketing approval by the FDA for the treatment of Dupuytren's contracture.

17 Sep 2009

CEO of WageWorks issues statement on health care reform plan

Following today's introduction of a health care reform plan by Senate Finance Committee Chairman Max Baucus (D-MT), Joe Jackson, chairman of Save Flexible Spending Plans and CEO of WageWorks, a benefits company based in San Mateo, California, issued the following statement:

17 Sep 2009

BioSpecifics Technologies' XIAFLEX receives marketing approval from FDA

BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products, today announced that the Arthritis Advisory Committee appointed by the U.S.

17 Sep 2009

FDA provides Orphan-Drug designation for Keryx' KRX-0401 to treat multiple myeloma

Keryx Biopharmaceuticals, Inc. today announced that KRX-0401 (perifosine) has received Orphan-Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma. In August, the Company announced that it had reached an agreement with the FDA regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial in relapsed/refractory multiple myeloma and that the study is expected to start by year-end.

16 Sep 2009

Keryx Biopharmaceuticals receives orphan-drug designation for a multiple myeloma drug

AEterna Zentaris Inc., ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc., its partner and licensee for perifosine in the North American market, has received orphan-drug designation for this compound from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma.

16 Sep 2009

Tips for saving health care costs

Lifescript.com, the leading women’s health website, today published its list of top 100 tips for slashing your family’s health care costs.

16 Sep 2009

Breast cancer prevention drugs may negatively affect patients

Three drugs, including tamoxifen, reduce a woman's chance of getting breast cancer, but each drug carries distinct potential harms of its own, according to a new report from HHS' Agency for Healthcare Research and Quality.

16 Sep 2009

Phase III EXTEND trial results of pixantrone announced

Cell Therapeutics, Inc. (CTI) today released updated 18-month follow-up clinical data for its phase III EXTEND (PIX 301) trial of pixantrone (BBR2778) for patients with advanced, relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL). Responses were evaluated by an Independent Assessment Panel that was blinded to patient assignment.

16 Sep 2009

eHealthInsurance's key questions to help women purchase health insurance plans

eHealthInsurance, the leading online source of health insurance for individuals, families and small businesses, today released a list of answers to questions frequently asked by women who call its customer care center. The customer care center includes a call center staffed with licensed insurance agents.

15 Sep 2009

Free medication reminder service launched for patients

Prescription medications are widely used in the U.S., with 47% of Americans using at least one prescription drug, according to the Center for Disease Control's report "Health, United States, 2008." Prescription drug use is even more widespread among the senior population, with 66% of those in the 45-65 age group and 87% of those aged 65 years and older on prescription medications.

15 Sep 2009

HealthInsight unveils value-based solutions to reduce health care costs

HealthInsight, provider of the only value-based health care administration platform, officially unveils a set of technology and services for health insurers, third-party administrators and employers that are proven to lower overall medical costs while improving the quality of care. The new platform will be used to determine and track health actions that are directly tied to benefit designs, which is instrumental in lowering health care costs.

15 Sep 2009

A.P. Pharma and Merial sign license and development agreement for a long-acting pain management product

A.P. Pharma (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it has entered into a license and development agreement with Merial, a world leading animal health company, for a long-acting pain management product.

15 Sep 2009

SXC collaborates with Allscripts to enhance e-prescribing solutions

SXC Health Solutions Corp. ("SXC" or the "Company") (NASDAQ: SXCI, TSX: SXC), today announced it has entered into a strategic relationship with Allscripts (NASDAQ: MDRX) to enhance the electronic prescribing (e-prescribing) options available to SXC's healthcare benefits management customers.

15 Sep 2009

Particle beam radiation therapy for cancer cure is better than traditional radiation method

Particle beam radiation therapy, a technology used to treat several types of cancer, is considered by some clinicians to be better than traditional radiation, but there is limited evidence about its safety compared with other types of radiation therapy, according to a new comparative effectiveness report funded by HHS' Agency for Healthcare Research and Quality.

15 Sep 2009

MHPA to hold policy briefing on issues for Medicaid health plans in health reform

The Medicaid Health Plans of America (MHPA), the leading trade association solely focused on representing Medicaid health plans, is holding a policy briefing on issues for Medicaid health plans in health reform. Issues will include Medicaid expansion, prescription drug rebate equalization for Medicaid managed care, and medical loss ratios.

15 Sep 2009

Cell Therapeutics submits Pediatric Investigation Plan to EMEA for pixantrone

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has submitted a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMEA) as part of the required filing process for approval of pixantrone for treating relapsed or refractory, aggressive non-Hodgkin's Lymphoma (NHL) in Europe. The PIP outlines how the company proposes to study the drug in children in order to benefit child health.

15 Sep 2009

Concept of wellness can yield greater savings

According to a new survey released today, 90 percent of plan sponsors believe that minimal attention to personal health and increased incidence of chronic illness such as diabetes and heart disease are at the root of rising health care costs.

14 Sep 2009

GTx to continue its toremifene Phase III high grade PIN clinical trial for prevention of prostate cancer

GTx, Inc. (Nasdaq: GTXI), today announced that following a planned safety review, an independent Data Safety Monitoring Board (DSMB) has recommended that the company continue as planned the pivotal Phase III clinical trial evaluating toremifene 20 mg for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia (PIN), a precancerous lesion of the prostate.

14 Sep 2009

Dyax' Phase 3 hereditary angioedema clinical program affirms reliability of its novel PROs

Dyax Corp. (NASDAQ:DYAX) today announced a study published evaluating the Company’s novel Patient Reported Outcome Measures (PROs) used to assess hereditary angioedema (HAE) attacks affirmed the PROs as valuable instruments in capturing HAE symptom severity and impact of treatment.

11 Sep 2009

NCOA supports Obama for improving Medicare’s delivery system

NCOA applauds President Obama's call for universal health care. Older Americans with Medicare know first-hand the benefits of universal coverage -- and they should be in the forefront of efforts to secure the same rights for their children and grandchildren.

11 Sep 2009

Prescription Drug News and Research

FDA Advisory Committee recommends marketing approval for Auxilium's XIAFLEX to treat Dupuytren's contracture

CEO of WageWorks issues statement on health care reform plan

BioSpecifics Technologies' XIAFLEX receives marketing approval from FDA

FDA provides Orphan-Drug designation for Keryx' KRX-0401 to treat multiple myeloma

Keryx Biopharmaceuticals receives orphan-drug designation for a multiple myeloma drug

Tips for saving health care costs

Breast cancer prevention drugs may negatively affect patients

Phase III EXTEND trial results of pixantrone announced

eHealthInsurance's key questions to help women purchase health insurance plans

Free medication reminder service launched for patients

HealthInsight unveils value-based solutions to reduce health care costs

A.P. Pharma and Merial sign license and development agreement for a long-acting pain management product

SXC collaborates with Allscripts to enhance e-prescribing solutions

Particle beam radiation therapy for cancer cure is better than traditional radiation method

MHPA to hold policy briefing on issues for Medicaid health plans in health reform

Cell Therapeutics submits Pediatric Investigation Plan to EMEA for pixantrone

Concept of wellness can yield greater savings

GTx to continue its toremifene Phase III high grade PIN clinical trial for prevention of prostate cancer

Dyax' Phase 3 hereditary angioedema clinical program affirms reliability of its novel PROs

NCOA supports Obama for improving Medicare’s delivery system

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News